Why are Imaging Core Labs Essential for Medical Device Trials?

As the scale of clinical trials continues to increase and the regulatory approval process is becoming more complex, the role of Contract Research Organizations (CROs) to oversee the conduct of these trials and the growing reliance on imaging to assess clinical endpoints are essential to the success of a clinical program and whether a medical device obtains regulatory approval. As a result, the ability to provide quality, reliable, and consistent image analysis and interpretation on the outcomes of therapies depends largely on radiologists. Although clinical symptoms or laboratory data are often used to determine treatment response, imaging is often preferred as a study endpoint because of its objectivity, ability to visualize and quantify changes in various anatomic areas, or measure the magnitude of a particular therapeutic response. Another benefit of central imaging core labs is the elimination of biases because the images are reviewed by independent radiologists as part of a Blinded Independent Central Review (BICR), which is the preferred method endorsed by the FDA. This is the unique value imaging core labs bring to the conduct of clinical research.

What Is an Imaging Core Lab?

An imaging core lab comprises a specialized team that manages all related imaging processes for clinical trials. Acting as a central hub, it guarantees that images collected across multiple sites are standardized, consistent, of high-quality, and analyzed according to validated protocols, ensuring that the rules of the protocols and criteria used to interpret the images are followed rigorously. These latter aspects of an imaging core lab have become even more important as the complexity of and reliance on imaging in clinical studies have grown tremendously in the past decade. From monitoring disease progression over time, evaluating treatment response, to identifying imaging biomarkers for disease diagnosis and monitoring, imaging science is now at the forefront of clinical trials, hence requiring robust centralized services to handle such data.

Unlike clinical site-level image interpretation that could be prone to bias and inconsistencies in the interpretation of images, an imaging core lab provides independent blinded reviews performed by board-certified radiologists with recognized expertise and qualifications in the relevant medical field being studied, thereby providing state-of-the art image analysis. Reader performance particularly as it relates to the issue of reproducibility is one of the most challenging aspects of an imaging core lab. This is especially relevant when double-blind reads with adjudication are selected for a trial where a high level of agreement between radiologists is required. In addition, consistency in the interpretation of the images is critical, whether a single reader study or one with dual radiologists. In order to maximize such consistency, it is imperative that the radiologists participating in the study undergo dedicated rigorous training. This is part of medical quality control services provided by imaging core labs. Imaging core labs also handle data management and compliance with regulatory standards, such as the FDA, ISO, and 21 CFR Part 11.

An imaging core lab transforms what could be a potential risk into a reliable, audit-ready asset for any trial. This provides incredible value to the clients, regardless of the imaging modality needed for the trial or specific endpoint of the study.

Some medical device manufacturers may underestimate the complexity related to imaging in multi-center trials. For example, the variability in image acquisition from site to site, the possible subjective interpretation of images because it is performed at the site where the patients are being treated, and inconsistent data can lead to costly delays, or possibly major regulatory setbacks. This is where an imaging core lab adds tremendous value, to the point of being indispensable to the conduct of a clinical study.

Key Functions

  • Imaging Protocol Development (Imaging Manual or Charter): Define imaging requirements and acquisition parameters prospectively for the clinical trial.
  • Site Training & Certification: Ensure every site captures images correctly, regardless of equipment differences.
  • Medical Quality Control: Continuous monitoring to prevent errors, enhance reproducibility and consistency among radiology readers through rigorous training, and maintain data integrity.
  • Centralized Reading: Independent, blinded interpretation (BICR) to eliminate bias.
  • Importance of Radiologists: Board-certified radiologists with relevant expertise in various therapeutic subspecialties involving the topic of the clinical study such as cardiology, vascular medicine, oncology, orthopedics, and neurology, and qualifications in advanced imaging modalities including CT, MRI, ultrasound, PET, and nuclear medicine.

Challenges Without an Imaging Core Lab

Managing the imaging aspects of a multi-center trial internally by a medical device company may seem cost-effective at first, but it introduces significant risks:

  • Inconsistent Image Acquisition/Data Quality and Variability: Each site may use different scanners, settings, and techniques. For example, in an orthopedic implant trial, one site might use a 1.5T MRI while another uses a 3T MRI, or sites may use various MR sequences producing images with different resolutions and contrast—making image comparisons and interpretation difficult.
  • Subjective Interpretation and Bias: Radiologists at the clinical sites involved in the study often know treatment assignments or may not have the required level of expertise in the specific area of the study. For example, in a cardiovascular device study, a mean vessel lumen measurement may differ among readers because of inconsistent and inadequate skill level by the radiology readers, rather than the actual performance of the medical device in question.
  • Regulatory Delays and Data Queries (Regulatory Compliance): Regulators expect imaging data to be standardized and reproducible. If the trial lacks centralized oversight, it risks being queried by the FDA, additional audits, or even rejection of the pre-selected imaging endpoints.
  • Costly Rescue Studies: Poor image quality or protocol deviations often require re-imaging or re-analysis mid-study. These unplanned steps could add months to the timeline and thousands of dollars to the budget.

How can an Imaging Core Lab Solve These Issues?

An Imaging Core Lab acts as quality and compliance partner, guaranteeing the accuracy and consistency of the imaging data to ensure it is audit-ready:

  • Standardized Imaging Protocols Across Clinical Sites: Imaging core labs are responsible for the creation of acquisition parameters prospectively (type of imaging and technical specifications) and standardized protocols across sites. In addition, anonymized imaging data are stored centrally and securely for easy access to radiologists. For example, in a neurovascular device trial, this would mean that every angiogram is acquired using the same intravascular contrast agent and image projections, eliminating the chance of variability.
  • Site Training and Certification: Before patient enrollment begins, sites are trained and certified to capture the images correctly. This prevents errors such as using incorrect slice thickness on MRI or CT and improper pullback speed on IVUS. In addition, the radiologist readers selected to interpret the images undergo training through a rigorous medical quality control process by the imaging core lab.
  • Independent Blinded Reviews: Imaging core labs provide centralized interpretation of images by experts (most often radiologists) who are blinded to treatment assignments. This ensures objective analysis and removes any bias compared to what could occur when the images are read at local clinical sites.
  • Continuous Image Quality Control: Images are checked in real time to ensure they comply with the specifications defined in the imaging manual/protocol. As an example, in oncology where tumor response relies on the RECIST guidelines which are based on precise unidimensional tumor size measurement, guaranteeing the quality of the imaging and of this measurement is paramount before the data is finalized and entered into the Case Report Forms (CRF).
  • Regulatory-Grade Data Management: Imaging core labs use validated systems that are compliant with the FDA, ISO, and 21 CFR Part 11, ensuring secure storage and audit-ready documentation.

For device manufacturers, this means greater confidence in using imaging endpoints for their studies and a smoother path to market.

Real-World Examples

  • Vascular Devices: In a stent trial using IVUS, one site might capture images at different pullback speeds than those obtained at another site. Such inconsistency could affect the accuracy of the vessel lumen measurements. A core lab would enforce the acquisition of consistent parameters and perform the analysis centrally, ensuring the accuracy of the reads.
  • Orthopedic Implants: MR imaging is often used to assess the success of bone integration after placement of an implant. If the slice thickness or MR sequences vary across sites, the data could become uninterpretable. A core lab would not only standardize these imaging parameters but would also interpret the images centrally and blindly by radiologists who are not involved in the study and would therefore not carry any potential biases.
  • Cardiovascular or Neurovascular Devices: Angiography trials require precise imaging projections (AP, lateral or various obliquities including RAO or LAO) and contrast media use. Without central oversight, clinical sites may deviate from the original imaging manual/protocol, possibly compromising the validity of the imaging endpoints. By certifying clinical sites and ensuring proper image quality, the core lab would address many of these potential pitfalls.
  • Oncology: Imaging is critically important in all oncology trials where imaging endpoints constitute the main endpoints of clinical trials. Whether it is progression-free survival (PFS), time to tumor progression (TTP), duration of response and other such endpoints, imaging is the key measure of a trial’s success. Criteria such as RECIST1.1, which consist of unidimensional tumor size measurements, are the most commonly used tumor response criteria. Given the numerous timepoints and complexity of imaging inherent in cancer trials, it is therefore critically important for companies engaged in oncology trials to retain the services of an imaging core lab to ensure that the correct imaging protocol and proper imaging sequences are obtained to guarantee consistency, standardization, and accurate interpretation and analysis of the imaging data.

When Should You Engage an Imaging Core Lab?

It is best to engage with an imaging core lab as early as possible during the planning phase of a clinical trial to ensure that any imaging needs are included in the clinical protocol. This can help avoid potentially expensive mid-study corrections.

Consider engaging an imaging core lab if the trial involves:

  • Complex Imaging Modalities: Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS), MRI, CT, angiography, nuclear imaging, molecular imaging, and others.
  • Imaging-Dependent Endpoints: When imaging is the primary or secondary endpoint for efficacy or safety.
  • Multi-Center Trials: Greater risk of variability across sites.

How to Choose the Right CRO Imaging Core Lab

Selecting the right imaging core lab is critical for the success of a clinical trial. Not all core labs offer the same level of expertise, experience in the therapeutic area in question, and regulatory compliance. Here are some key factors to consider:

1. Regulatory Expertise

Look for an imaging core lab with proven experience in medical device trials and compliance with the FDA, ISO, and 21 CFR Part 11 standards. This ensures the imaging data will meet regulatory expectations and withstand audits.

2. Modality-Specific Knowledge

Your device may require specialized imaging, such as Optical Coherence Tomography (OCT) or Intravascular Ultrasound (IVUS) for coronary artery stents, MRI for orthopedic implants, or CT for oncology trials. Choose an imaging core lab with demonstrated expertise and experience in the therapeutic area and imaging modality in question.

3. Technology and Integration

Ask about the lab’s technology stack:

  • Does it use validated imaging platforms?
  • Can it integrate with the Sponsor’s Electronic Data Capture (EDC) system for seamless data flow?
  • Does it offer AI-assisted analysis or advanced visualization tools?

4. Quality Control Processes

Ensure the lab has robust site training and certification programs, real-time image quality checks, and blinded review procedures. These processes prevent variability and reduce the risk of costly rescue studies.

5. Global Reach and Scalability

If your trial spans multiple countries, confirm the imaging core lab can handle multi-regional logistics, including data privacy compliance (GDPR) and language support for site training.

6. Proven Track Record

Request case studies or references. An imaging core lab with experience in similar device trials and no previous audit findings is a strong indicator of reliability and excellence.

Frequently Asked Questions (FAQs)

What types of imaging modalities do core labs support?

Imaging Core Labs typically support a wide range of imaging modalities, including Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS), MRI, CT, X-ray, angiography, and ultrasound. As mentioned above, these imaging modalities are essential to assess device performance, technical efficacy, and safety, as imaging is often the primary endpoint of a clinical trial. Imaging Core labs can also handle emerging imaging technologies such as molecular imaging involving new radiotracers, new imaging software based on artificial intelligence (organ or tumor segmentation), and imaging biomarkers, ensuring that even complex imaging requirements can be standardized and validated across all trial sites.

How does an imaging core lab ensure regulatory compliance?

Compliance is achieved through validated processes and systems that meet FDA, ISO, and 21 CFR Part 11 requirements. Imaging core labs develop standardized imaging acquisition protocols, provide site training and certification, and perform blinded, independent image reviews to eliminate bias. They also maintain audit-ready documentation, implement secure data transfer and storage, and ensure adherence to privacy regulations such as GDPR. This rigorous approach minimizes regulatory risk and accelerates approval timelines.

Can an imaging core lab help reduce trial timelines?

Absolutely. Imaging core labs streamline workflow by centralizing the management of all imaging, performing real-time quality checks, and providing rapid turnaround for image analysis. This proactive approach prevents delays caused by poor image quality or inconsistent acquisition, which often lead to costly rescue studies. Additionally, by integrating imaging requirements early in protocol development, imaging core labs help avoid mid-study corrections and ensure that imaging endpoints are met efficiently, saving both time and resources.


Jeff Geschwind, MD

Jeff Geschwind, MD

Dr. Jeff Geschwind, Medical Director–Oncology, Image-Guided Therapy, and Imaging Core Lab at NAMSA, is an internationally recognized leader in Interventional Oncology and liver cancer treatment. He earned his medical degree from Boston University, completed residency at UCSF as an NIH Resident-Scholar, and fellowship at Johns Hopkins, where he later served as Director of Vascular and Interventional Radiology and Professor of Radiology, Surgery, and Oncology. He also chaired Radiology and Biomedical Imaging at Yale School of Medicine. With nearly 300 publications (H-Index 87), he authored the first textbook on Interventional Oncology, co-edited Abram’s Angiography, and led over 50 clinical trials. His expertise spans oncology, interventional radiology, liver disease, imaging science, and immune-oncology. A recipient of numerous prestigious awards, including the Alexander Margulis Award and Albert Nelson Marquis Lifetime Achievement Award, he continues to advise companies on clinical strategy and medical innovation.